Correction to Lancet Diabetes Endocrinol 2019; published online March 1. DOI:10.1016/ S2213-8587(19)30066-X
- PMID: 30872122
- DOI: 10.1016/S2213-8587(19)30109-3
Correction to Lancet Diabetes Endocrinol 2019; published online March 1. DOI:10.1016/ S2213-8587(19)30066-X
Erratum for
-
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.Lancet Diabetes Endocrinol. 2019 May;7(5):356-367. doi: 10.1016/S2213-8587(19)30066-X. Epub 2019 Mar 1. Lancet Diabetes Endocrinol. 2019. PMID: 30833170 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
